| Name | Title | Contact Details |
|---|
MVNA serves individuals and families that are economically disadvantaged and at high risk for critical social and health issues. More than 90% of MVNA clients residing in Minneapolis are living at or below 200% of Federal Poverty Guidelines. Many of
Neuralstem is a dual platform regenerative medicine company. The company`s technology enables the production of regionally specific, physiologically relevant neural stem cells for therapeutic use for the treatment of central nervous system (CNS) diseases and has enabled the discovery of a library of patented small molecule neurogenic compounds to treat psychological and cognitive disorders. Neuralstem`s small molecule drug discovery program screens human neural stem cell lines for compounds that may stimulate neurogenesis in the brain, possibly reversing pathologies associated with certain CNS conditions. The company`s lead compound, NSI-189, has completed FDA Phase Ia and Ib safety trials for the treatment of major depressive disorder (MDD). Neuralstem is expecting to launch a Phase II study for MDD in 2015. Neuralstem`s first stem cell therapy product, NSI-566, a spinal cord-derived neural stem cell line, is in ongoing clinical trials to treat amyotrophic lateral sclerosis (ALS, or Lou Gehrig`s disease), for which it has received orphan status designation by the FDA. Dosing in a phase IIa trial was completed in July, 2014. The next trial is anticipated to commence in 2015. In addition to ALS, the company is conducting an NSI-566 Phase I trial in chronic spinal cord injury, with NSI-566 clinical development also underway to treat ischemic
Araceli Biosciences is a company that develops scientific instrumentation to improve outcomes in tissue and cell based biomarker discovery, drug discovery and drug development.
Clipper America Inc is a Houston, TX-based company in the Healthcare, Pharmaceuticals, & Biotech sector.
InnFocus, Inc., an early stage company pioneering a microsurgical solution for glaucoma.InnFocus is an ophthalmology company founded in 2003 with extensive biomaterials experience that develops and provides next generation products for glaucoma surgery. Glaucoma is a disease for which there is no cure, is the second leading cause of blindness in the world and afflicts an estimated 60 million people worldwide.